Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury

Inclusion Criteria: * RACUM ≥6 * ALTs ≥2ULN, but TBiL is ≤ 3 ULN.It may be associated with AST or ALP or TBiL exceed the upper limit of normal * Liver biochemical abnormalities duration of no more than three months * Patients need to fully understand and sign the inform consent form. Exclusion Criteria: * The liver injury is caused by other diseases, such as virus hepatitis, alcohol and non-alcohol fatty liver disease or the autoimmune liver disease. * The patients with the acute hepatic failure or hepatic decompensation, such as hepatic encephalopathy, ascites, albumin is ≤ 35g/L, prothrombin time is elongated more than 2 seconds compared to its normal range. * The value of the TBiL is \> 3ULN. * The value of serum creatinine is \> 1.5ULN. * Patients who have severe organic diseases on heart, lungs, brain, kidney and gastrointestinal tract. * Patients who are taking the drugs that might interfere the trial. * Patients who are allergic or intolerant to the study drug. * Patients who are not able to express the chief complaint, for example, the patients with psychosis and severe neurosis. * Patients who are compliant with protocol. * Women who are pregnant, breast-feeding or with childbearing potential. * Patients who have attended other clinical trials within 3 months. * Not appropriate to be included after assessing by the investigators. ULN=Upper Limited Normal